The demand within the global market for immunoprotein diagnostic testing has gained momentum on account of key developments in the field of medical treatment and diagnostics. Immunoprotein, in essence, refer to blood proteins that play a key role in the functioning of the immune system. They endow immunological activity, and hence, are an important component of the human body. Immunoproteins show an abrupt rise in their concentration in the blood as a result of unhealthy immune functioning of the body. This abnormal rise in their concentration can act as a trustable indicator of several diseases or infections in the body. Several research organizations and laboratories have been engaged in the study of immunoproteins and their potential to act as indicators of diseases. This is expected to propel demand within the global market for immunoprotein diagnostic testing and shall open doors for the inflow of commendable revenues into this market.

The rising geriatric population coupled with an all-time high incidence of chronic diseases has given an impetus to the growth of the global market for immunoprotein diagnostic testing. Moreover, the upswing in demand for immunoprotein diagnostic testing can also be attributed to the prevalence of infectious diseases across the globe. Unhygienic living conditions, especially in the underdeveloped regions, have also led to the occurrence of diseases and infections. This has brought the global market for immunoprotein diagnostic testing under the spotlight of attention.

A report by Transparency Market Research (TMR) on the global market for immunoprotein diagnostic testing builds on the key factors that have supported the growth of the market. The report predicts that the global market for immunoprotein diagnostic testing would reach a value of US$15.3 bn by 2019-end, growing at a stellar CAGR over the forecast period from 2013 to 2019.

Chemiluminescence Technology to Lead Other Segments

On the basis of technology used for immunoprotein diagnostic testing, the demand for chemiluminescence assay has been rising at a robust rate as against other technologies. This can be attributed to the sensitivity, easy usage, and wide application scope of this technology. Furthermore, ELISA technologies are up for a chase for greater market share against the aforementioned segment. The radioimmunoassay segment has been tracing a descending graph of growth due to several regulations imposed by the government on the use of radioactive substances. On the basis of application, immunoprotein diagnostic testing can be segmented into oncology, endocrine testing, testing of infectious diseases, allergy testing, toxicology testing, and autoimmune disease testing. Amongst these, oncology testing through immunoprotein diagnosis has attracted the highest demand over the past decade.

North America to Emerge as Regional Market Leader

The US has witnessed a surge in the incidence of chronic diseases over the past few years, and this has necessitated the presence of a robust diagnostic system across the country. Furthermore, medical practitioners in Canada and the US have been making ardent efforts to ensure that immunoprotein testing is given prime impetus. Owing to these factors, the market for immunoprotein diagnostic testing in North America has been expanding at a robust rate over the past few years. Besides this, the markets for immunoprotein diagnostic testing in Europe, the Middle East and Africa (MEA), Latin America, and Asia Pacific (APAC) are also projected to expand their share in the global market share.

Some of the key players in the global market for immunoprotein diagnostic testing are Abcam PLC, Roche, Diasorin, Abbott Laboratories, Enzo Life Sciences, Randox Laboratories, The Binding Site, and Siemens.

Immunoprotein diagnostic testing market is continuously fueled with innovative technologies which are shrinking product life cycle and also expanding the boundaries of market. These innovations have also increased the scope of application in various medical fields. The market for immunoprotein diagnostic testing has been segmented according to various immunoproteins, which help in immune response modulation. These include immunoglobulins, complement system proteins, C-reactive protein (CRP), haptoglobin, prealbumin and free light chains (FLC) of immunoglobulins. Each of these proteins plays a characteristic role in the immune response, and hence the level of these immunoproteins has been considered as an indication of diseased state.
 
Immunoprotein diagnostic testing market has been studied from the perspective of technology platforms such as enzyme linked immunosorbent assay (ELISA), chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, radioimmunoassay, and immunoprotein electrophoresis. Enzyme linked immunosorbent assay is the most widely used technique in the diagnosis of various diseases globally. On the other hand, the market for chemiluminescence assay technology was found to be fastest growing segment owing to broad applications in disease diagnosis, drug testing, oncology and various others.   
 
Further, immunoprotein diagnostic testing market has also been segmented according to application in diagnosis of various diseases. These include infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and autoimmune disease testing. Oncology segment is growing rapidly owing to increased disease prevalence and high cost of assay kits. Geographically, the immunoprotein diagnostic testing market has been segmented into four major regions, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). Each of these four geographies is further segmented according to assay technologies. Immunoprotein diagnostic testing market report also details market attractiveness analysis for these geographies. The analysis is based on various factors such as current stage of life cycle, market size, customer base, market competition, and annual growth rate.  
 
Immunoprotein diagnostic testing market is subjected to various micro as well as macro economic factors. The impact of these factors has been studied to forecast the future trends. The report also provides detailed Porter’s five forces analysis of the immunoprotein diagnostic testing market. Based on in depth analysis and comprehensive market study, key factors driving and restraining the market have been discussed. Moreover lucrative opportunities and relevant recommendations for sustainable growth in the immunoprotein diagnostic testing market also have been suggested.  Each of the market segments has been analyzed on the basis of current and future market size for the period 2011 to 2019, in terms of revenue (USD million), considering 2011 and 2012 as the base years. The compounded annual growth rate (% CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. An exhaustive heat map analysis of key market players such as Abbott Laboratories, Abcam PLC, Diasorin, Enzo Life Sciences, Randox Laboratories, Roche, Siemens, The Binding Site, and Thermo Fisher Scientific is provided in this report. Each of these key market players are profiled in the report considering parameters such as company overview, financial overview, product portfolio, business strategies and recent developments. 
 
The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players’ product literature, annual reports, and press releases supports the market forecast analysis. The 99 pages immunoprotein diagnostic testing market reports described various market dynamics in 30 figures and charts and 9 tables.
.